Fewer health insurance claims have been made while elective surgery is in hiatus but
-Unlikely benefits from the pandemic will accrue to the
-Confident second half earnings will be ahead of the prior comparable half
-Private health insurance affordability still the pressing issue
The company has indicated it will return any "permanent" benefit from lower claims - as opposed to simple deferral of treatment - to policyholders, yet several brokers assert the amount and impact will be hard to ascertain.
Therefore, its commitment is simply to return permanent ancillary claim savings if they exceed this level. This allows the insurer time to assess the full impact of savings, in Credit Suisse's view, instead of having to refund premiums and then run the risk too much has been returned.
What appears likely is that little if any of the benefits from the pandemic will accrue to the balance sheet.
ASIC (
Many non-essential procedures/claims may not end up being made because of concerns around infections at hospitals as well as PPE (personal protective equipment) shortages and supply constraints, so there still could be a material benefit for insurers.
Only 1% of customers have so far suspended policies, largely from the younger cohort, and
The company is likely to be one of the few where its FY20 operating earnings are resilient, in Goldman Sachs' view. Beyond this, the broker, not one of the seven monitored daily on the FNArena database, believes the outlook for the industry is difficult, because a softer economic backdrop that will impact on premium growth, and retains a Sell rating with a
Out-of-Hospital Care
Over the longer term,
This is a rare opportunity for the government, Credit Suisse asserts, to trial reforms before implementation, as the pandemic has provided an insight into alternative care options, and could be used to address affordability and participation in the industry.
Citi shares the view that demand for at-home and digital health care alternatives will accelerate and, providing the government supports the initiative, also believes there is potential for material cost savings on claims, albeit over the longer term.
Affordability
Ord Minnett upgrades to Hold from Lighten, assessing health insurers are defensive exposures in tough economic times. The broker's main concern centres on government constraints over the last two years.
Affordability is indeed the pressing issue, compounded by the economic impact of the pandemic,
Goldman Sachs points to the dilemma, in that rising government debt following the pandemic will limit reform options but will also add impetus to attempts to contain public health expenditure. Citi agrees reform options are also more limited, given the tougher fiscal position, and this raises the question of whether the private sector needs to shoulder a larger share of health care funding.
Hence, the proposed fringe benefits tax deduction for corporate health insurers would now appear highly unlikely. Yet, as affordability pressures are likely to become more prevalent, the broker notes with interest that
Citi assesses the dividend yield is likely to prove attractive, given many other stocks have sustained reductions to their dividends, but remains wary about the potential impact in the medium term from a deteriorating economy.
Amid limited downside earnings risk, a strong balance sheet and potential for favourable reforms ahead, Credit Suisse judges the stock relatively safe in the current environment.
FNArena's database has six Hold ratings and one Buy (Credit Suisse) for
FNArena is proud about its track record and past achievements: Ten Years On
All material published by
© 2020 Acquisdata Pty Ltd., source